Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avalo Therapeutics Q2 EPS $(1.92) Misses $(1.42) Estimate; Cash, Cash equivalents And Short-term Investments Were $113.3M As Of June 30

Author: Benzinga Newsdesk | August 07, 2025 06:17am
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(1.42) by 35.5 percent. This is a 86.35 percent increase over losses of $(14.07) per share from the same period last year.

Posted In: AVTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist